Obulytix
Obulytix leverages proprietary phage lysin-based antibiotics technology to combat antibiotic-resistant bacteria, offering specificity, absence of resistance development, and the capability to eradicate chronic infections using nature.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
* | €4.0m | Early VC | |
| Total Funding | 000k | ||
Related Content
Obulytix is a biotechnology company that spun out of Ghent University and KU Leuven, and is focused on the discovery and development of enzyme-based antibiotics to combat antimicrobial resistance. The company has developed a platform for hit-to-lead development of phage lysins, which is leveraged by artificial intelligence to analyze thousands of variants and identify the most promising candidates.
Obulytix's business model is centered on research and development, with the goal of developing a new class of antibiotics that can be used to treat infections caused by drug-resistant bacteria. The company's primary clients are in the healthcare and pharmaceutical industries, and it operates in the global antibiotics market. Obulytix's revenue is likely generated through a combination of research grants, partnerships with pharmaceutical companies, and licensing agreements for its technology.
Keywords: biotechnology, antibiotics, antimicrobial resistance, phage lysins, artificial intelligence, drug discovery, healthcare, pharmaceutical, enzyme-based, R&D